- Difference in Tumor Area as a Predictor of a Pathological Complete Response for Patients With Locally Advanced Rectal Cancer
-
Ji Hyeong Song, Yo-Han Park, Sang Hyuk Seo, Anbok Lee, Kwang Hee Kim, Min Sung An, Ki Beom Bae, Kwan Hee Hong, Jin Won Hwang, Ji Hyun Kim, Hyun Seok Jung, Ki Jung Ahn
-
Ann Coloproctol. 2017;33(6):219-226. Published online December 31, 2017
-
DOI: https://doi.org/10.3393/ac.2017.33.6.219
-
-
4,182
View
-
62
Download
-
4
Web of Science
-
4
Citations
-
Abstract
PDF
- Purpose
This study was conducted to discover the clinical factors that can predict pathologically complete remission (pCR) after neoadjuvant chemoradiotherapy (CRT), so that those factors may help in deciding on a treatment program for patients with locally advanced rectal cancer. MethodsA total of 137 patients with locally advanced rectal cancer were retrospectively enrolled in this study, and data were collected retrospectively. The patients had undergone a total mesorectal excision after neoadjuvant CRT. Histologic response was categorized as pCR vs. non-pCR. The tumor area was defined as (tumor length) × (maximum tumor depth). The difference in tumor area was defined as pre-CRT tumor area – post-CRT tumor area. Univariate and multivariate logistic regression analyses were conducted to find the factors affecting pCR. A P-value < 0.05 was considered significant. ResultsTwenty-three patients (16.8%) achieved pCR. On the univariate analysis, endoscopic tumor circumferential rate <50%, low pre-CRT T & N stage, low post-CRT T & N stage, small pretreatment tumor area, and large difference in tumor area before and after neoadjuvant CRT were predictive factors of pCR. A multivariate analysis found that only the difference in tumor area before and after neoadjuvant CRT was an independent predictor of pCR (P < 0.001). ConclusionThe difference in tumor area, as determined using radiologic tools, before and after neoadjuvant CRT may be important predictor of pCR. This clinical factor may help surgeons to determine which patients who received neoadjuvant CRT for locally advanced rectal cancer should undergo surgery.
-
Citations
Citations to this article as recorded by 
- Particular aspects of treating rectal cancer: The watch and wait approach
Diana Andreea Draghici, Alexandru Rares Stoian, Vlad Andrei Porojan, Oana Ilona David, Ştefan Bedereag, Anda Natalia Ciuhu, Andrei Haidar, Dragoş Crețoiu, Carmen Elena Condrat, Valentin Titus Grigorean Journal of Cancer Research and Therapeutics.2023; 19(2): 461. CrossRef - Predicting stage ypT0–1N0 for nonradical management in patients with middle or low rectal cancer who undergo neoadjuvant chemoradiotherapy: a retrospective cohort study
Jeehye Lee, In Jun Yang, Jung Wook Suh, Hong-min Ahn, Heung-Kwon Oh, Duck-Woo Kim, Young-Hoon Kim, Kyoung Ho Lee, Sung-Bum Kang Annals of Surgical Treatment and Research.2022; 103(1): 32. CrossRef - Radiotherapy after local excision of rectal cancer may offer reduced local recurrence rates
H. J. S. Jones, S. Goodbrand, R. Hompes, N. Mortensen, C. Cunningham Colorectal Disease.2019; 21(4): 451. CrossRef - ‘Watch and wait’ in rectal cancer: summary of the current evidence
Jason On, Emad H Aly International Journal of Colorectal Disease.2018; 33(9): 1159. CrossRef
|